-
Tempus Could Gain Share In AI Health Care Market Poised To Grow By Over 30%
Tuesday, July 9, 2024 - 12:26pm | 454Read More...Tempus AI Inc (NASDAQ:TEM) announced last week it was granted advanced diagnostic laboratory test status for its next-generation sequencing assay. These analysts provide their initial takeaways from the stock. BofA Securities On Tempus Analyst Michael Ryskin initiated coverage with a Buy rating and...
-
Citi Loses Some Confidence In Illumina Following Disappointing Guidance
Tuesday, October 11, 2016 - 7:30am | 290Read More...Illumina, Inc. (NASDAQ: ILMN) preannounced Q3 revenues short of estimates, marking the fourth miss in the last six quarters. The company’s Q4 revenue projection also came in short. There is no confidence in Illumina’s near-term performance, and “forecasting capabilities have...
-
UPDATE: Citigroup Reiterates On Cepheid Following Positive Data
Thursday, December 4, 2014 - 11:07am | 114Read More...In a report published Thursday, Citigroup analyst Daniel Arias reiterated a Buy rating on Cepheid (NASDAQ: CPHD), and raised the price target from $52.00 to $62.00. In the report, Citigroup noted, “Following positive data shown at the Nov. AMP mtg, CPHD expects CE mark approval for their HIV Viral...
